Metastatic bladder cancer: Advances in treatment

European Journal of Cancer Part A

Volumn 33, Issue SUPPL. 1, 1997, Pages

  Stadler, W M ^a   Kuzel, T M ^b   Raghavan, D ^c   Levine, E ^c   Vogelzang, N J ^a   Roth, B ^d   Dorr, F A ^e  

^a UNIVERSITY OF CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d INDIANA UNIVERSITY   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Bladder cancer; Chemotherapy; Clinical trials; Gemcitabine; Review

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DOXORUBICIN; GALLIUM NITRATE; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

BLADDER CANCER; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; METASTASIS; PRIORITY JOURNAL;

EID: 0030968340     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00337-1     Document Type: Conference Paper

References (55)

1. Wingo PA, Tong T, Bolden S. Cancer Statistics CA 1995, 45, 8-30.
2. Raghavan D, Shipley WU, Garnick MD, et al. Biology and management of bladder cancer. New Engl J Med 1990, 322, 1129-1138.
3. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992, 10, 1066-1073.
4. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990, 8, 1050-1055.
5. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985, 133, 403-407.
6. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989, 64, 2448-2458.
7. Conner JP, Olsson CA, Benson MC, et al. Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of the urinary bladder: cause for concern. Urology 1989, 34, 353-356.
8. Igawa M, Kadena H, Usui T. Long term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in complete response patients. J Urol 1994, 151, abstract no. 454.
9. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988, 318, 1414-1422.
10. Moore MJ, Iscoe N, Tannock IF. A phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma. J Urol 1993, 150, 1131-1134.
11. Logothetis C, Sella A, Amato R, et al. Escalated MVAC ± rhGMCSF in patients with advanced metastatic transitional cell carcinoma of the bladder. J Urol 1993, 149, abstract no. 318.
12. Loehrer PJ, Elson P, Dreicer R, et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1994, 12, 483-488.
13. Seidman AD, Scher HI, Gabrilove JL, et al. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 1993, 11, 408-414.
14. Levine E, Raghaven D. MVAC for bladder cancer-time to move forward again. J Clin Oncol 1993, 11, 387-389.
15. Crawford ED, Saiers JH, Baker LH, et al. Gallium nitrate in advanced bladder carcinoma: A Southwest Oncology Group study. Urology 1991, 38, 355-357.
16. Seligman PA, Crawford ED. Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate. J Natl Cancer Inst 1991, 83, 1582-1584.
17. Einhorn LH, Roth BJ, Ansari R, et al. Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 1994, 12, 2271-2276.
18. Dreicer R, Roth B, Propert K, et al. Vinblastine, ifosfamide, and gallium nitrate (VIG) in advanced carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol 1995, 14, abstract no. 246.
19. Logothetis C, Dieringer P, Ellerhorst J, et al. A 61% response rate with 5-fluorouracil, interferon-α2b and cisplatin in metastatic chemotherapy-refractory transitional cell carcinoma. Proc Am Assoc Cancer Res 1992, 33, abstract no. 221.
20. Bacoyiannis C, Skarlos D, Aravantinos G, et al. Cisplatin, interferon A2B and 5-fluorouracil for advanced urothelial cancer: a phase II study. Proc Am Soc Clin Oncol 1995, 14, abstract no. 234.
21. Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium:a phase II trial of the eastern cooperative oncology group. J Clin Oncol 1994, 12, 2264-2270.
22. Yagoda A. Phase II trials in patients with urothelial tumors: Memorial Sloan-Kettering Cancer Center. Cancer Chemother Pharmacol 1983, 11 (Suppl), 9-12.
23. Herr HW. Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer. J Urol 1980, 123, 853-857.
24. Peters PC, O'Neill MR. Cis-diamminedichloroplatinum as a therapeutic agent in metastatic transitional cell carcinoma. J Urol 1980, 12, 375-377.
25. Merrin C. Treatment of advanced bladder cancer with cis-diamminedichloroplatinum II: a pilot study. J Urol 1978, 119, 493-495.
26. Soloway MS, Ikard M, Ford K. Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer. Cancer 1981, 47, 476-480.
27. De Lena M, Lorusso V, Lacobellis U, Marzullo F, Maiello E, Crammarosa A. Cis-diamminedichloroplatinum activity in bidimensionally measurable metastatic lesions of bladder carcinoma. Tumori 1984, 70, 85-88.
28. Oliver RTD, Newlands ES, Wiltshaw E, Malpas JS. A phase II study of cis-platinum in patients with recurrent bladder carcinoma. Br J Urol 1981, 53, 444-447.
29. Rossof AM, Talley RW, Stephens RL, et al. Phase II evaluation of cis-dichlorodiammineplatinum (II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group study. Cancer Treat Rep 1981, 63, 1557-1564.
30. Fagg SI, Dawson-Edwards P, Hughes MA, Latief TN, Rolfe EB, Fielding JWL. Cis-diamminedichloroplatinum (DDP) as initial treatment of invasive bladder cancer. Br J Urol 1984, 56, 296-300.
31. Raghavan D, Pearson B, Cuval P, et al. Initial intravenous cis-platinum therapy; improved management for invasive high-risk bladder cancer. J Urol 1985, 133, 399-402.
32. Turner AG, Hendry WF, Williams GB, Bloom HJG. The treatment of advanced bladder cancer with methotrexate. Br J Urol 1977, 49, 673-678.
33. Hall RR, Bloom HJG, Freeman JR, Nawrocki A, Wallace DM. Methotrexate treatment for advanced bladder cancer. Br J Cancer 1977, 35, 40-51.
34. Gad-el-Mawla NH, Hamsa R, Cairns J, Anderson T, Ziegler JL. Phase II analysis of methotrexate in carcinoma of the bilharzial bladder. Cancer Treat Rep 1978, 62, 1075-1076.
35. Natale RB, Yagoda A, Watson RC, Whitmore WF, Blumenreich M, Braun DW. Methotrexate: an active drug in bladder cancer. Cancer 1981, 47, 1246-1250.
36. Turner AG. Methotrexate for advanced bladder cancer. Cancer Treat Rep 1981, 62, 183-186.
37. Oliver RTD. Methotexate as selvage or adjunctive therapy for primary invasive carcinoma of the bladder. Cancer Treat Rep 1981, 65, 179-182.
38. Oliver RTD, England HR, Risdon RA, Blandy JP. Methotrexate in the treatment of metastatic and recurrent primary transitional cell carcinoma. J Urol 1984, 131, 483-485.
39. Hall RR, Newling DWW, Ramsden PD, Richards B, Robinson MRG, Smith PH. Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol 1984, 56, 668-672.
40. Blumenreich MS, Yagoda A, Natale RB, Watson RC. Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors. Cancer 1982, 50, 435-438.
41. Richards R, Newling D, Fossa S, et al. Vincristine in advanced bladder cancer; an EORTC phase II trial. Cancer Treat Rep 1983, 6, 575-578.
42. Gad-el-Mawla N, Ziegler J, Hamza R, Elserafi M, Khaled H. Phase II chemotherapy trials of 5-FU, cyclophosphamide, ifosfamide, and vincristine in carcinoma of the bilharzial bladder. Cancer Treat Rep 1984, 68, 419-420.
43. Pavone-Mascaluso M, EORTC Genitourinary Cooperative Group A. Single drug chemotherapy of bladder cancer with Adriamycin, VM-26, or bleomycin. Eur Urol 1976, 2, 138-141.
44. O'Bryan RM, Baker LH, Gottlieb JE, et al. Dose-response evaluation of Adriamycin in human neoplasm. Cancer 1977, 39, 1940-1948.
45. Yagoda A, Watson RC, Whitmore WF, Grabstald H, Middleman MF, Krakoff IH. Adriamycin in advanced urinary tract cancer; experience in 42 patients and review of the literature. Cancer 1977, 9, 79-285.
46. Knight EW, Pagand EM, Hahn RG, Horton J. Comparison of 5-FU and doxorubicin in the treatment of carcinoma of the bladder. Cancer Treat Rep 1983, 67, 514-515.
47. Gagliano R, Levin H, El-Bolkainy MN, et al. Adriamycin versus Adriamycin plus cis-dichlorodiammineplatinum (II) in advanced transitional cell bladder carcinoma; a Southwest Oncology Group study. Am J Clin Oncol 1983, 6, 215-218.
48. Ducheck M, Edsmyr F, Naeslund I. 5-Fluorouracil in the treatment of recurrent cancer of the urinary bladder. In Pavonelmacaluso M, Smith P, Edsmyr F, eds. Bladder Tumors and Other Topics in Urologic Oncology. New York, Plenum Press, 1980, 381-385.
49. Smalley RV, Bartolucci AA, Hemstreet G, et al. A phase II evaluation of a 3 drug combination of cyclophosphamide, doxorubicin, and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. J Urol 1981, 125, 191-195.
50. Fossa SD, Gudmundsun TE. Single-drug chemotherapy with 5-FU and Adriamycin in metastatic bladder carcinoma. Br J Urol 1981, 53, 320-323.
51. Seidman AD, Scher HI, Heinemann MH, et al. Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer 1991, 68, 2561-2565.
52. Otaguro K, Ueda K, Niijima T, et al. Clinical evaluation of Z4942 (ifosfamide) for malignant urological tumors. Hinyokika Kiyo 1981, 27, 459-462.
53. Witte R, Loehrer P, Dreicer R, et al. Ifosfamide in advanced urothelial carcinoma: an ECOG trial. Proc Am Soc Clin Oncol 1993, 12, abstract no. 230.
54. Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994, 5, 182-184.
55. De Lena M, Larusso V, Amadori D, et al. Gemcitabine in resistant stage IV bladder cancer: a phase II study. Proc ECCO 1995, abstract no. 1146.